A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME)

Trial Profile

A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs THR 317 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Sponsors ThromboGenics
  • Most Recent Events

    • 11 May 2017 According to a ThromboGenics media release, first results are expected in H1 2018.
    • 10 Jan 2017 According to a ThromboGenics media release, first patients has been enrolled in this trial. The first results from the study are expected in Q1 2018.
    • 23 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top